Back to search
FDAFDA · Food and drugs·Recall number D-0173-2024

CITALOPRAM Tablets, USP, 20MG, 100 Tablets, Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 0378-6232-01

Published January 3, 2024 · Recall initiated: January 26, 2022

Summary

FDA records drug Class II recall D-0173-2024, published January 3, 2024 and initiated January 26, 2022. Recalling firm: CARDINAL HEALTHCARE; Status: Terminated; Reported quantity: 1 unit; Lot: Batch 3131748. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

What to do

Voluntary: Firm initiated · Letter

Get an email if CITALOPRAM has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CITALOPRAM
Manufacturer
CARDINAL HEALTHCARE
Distributor
Nationwide USA
UPC
0303786232017
Lot
Batch 3131748
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was CITALOPRAM Tablets, USP, 20MG, 100 Tablets, Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 0378-6232-01 recalled?

Yes. FDA published recall D-0173-2024 on January 3, 2024. Reported hazard: CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CITALOPRAM. UPC: 0303786232017.